Search / Trial NCT00000879

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Pregnancy Pregnancy Complications, Infectious Aids Vaccines Disease Transmission, Vertical Avipoxvirus Hiv Preventive Vaccine Hiv Therapeutic Vaccine

ClinConnect Summary

Transmission of HIV from an untreated infected mother to her offspring is thought to occur to some infants perinatally and others at parturition. It is possible that administration of an immunogenic vaccine can reduce the vertical transmission of HIV-1 or moderate its course in infected infants. Successful early sensitization to HIV epitopes might succeed in preventing HIV infection. Alternately, the enhancement of HIV-specific immune function might also succeed in modifying HIV replication and affecting disease progression.

Sixty infants are treated in this randomized, double-blind study;...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • The infant may be eligible if the mother:
  • Is HIV-positive.
  • Is willing to follow the study guidelines.
  • Had her baby at Week 37 of pregnancy or later.
  • Exclusion Criteria
  • The infant will not be eligible if the mother:
  • Has hepatitis B.
  • Is breast-feeding her baby.
  • Used certain medications during pregnancy.
  • The infant will not be eligible if he/she:
  • Is more than 3 days old at study entry.
  • Has a serious infection or life-threatening illness.

Trial Officials

John Lambert

Study Chair

Daniel Johnson

Study Chair

Stuart Starr

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Boston, Massachusetts, United States

San Francisco, California, United States

Chicago, Illinois, United States

Baltimore, Maryland, United States

Worcester, Massachusetts, United States

New York, New York, United States

Long Beach, California, United States

Torrance, California, United States

Syracuse, New York, United States

Philadelphia, Pennsylvania, United States

New Orleans, Louisiana, United States

Philadelphia, Pennsylvania, United States

Orange, California, United States

New York, New York, United States

Chicago, Illinois, United States

Bronx, New York, United States

Seattle, Washington, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials